Company
CSL
ASX:CSL
Plasma immunoglobulins, gene therapy.
At a glance
- Listing
- ASX:CSL
- Category
- ASX listed
- Headquarters
- Melbourne
- Market cap
- ~A$53B
Thesis
Why it is in this universe
- Category
- ASX listed
- Market
- Australia
- Recent inflection
- Decade-low price; ~US$5B Vifor impairment; demerging Seqirus (flu vaccines) by end FY26.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:CSL |
| Secondary listing | None |
| Market cap | ~A$53B |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Melbourne
- Website
- No site on file
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
Decade-low price; ~US$5B Vifor impairment; demerging Seqirus (flu vaccines) by end FY26.
Common questions
- Why does variis track CSL?
- Plasma immunoglobulins, gene therapy.
- Is CSL publicly listed?
- Yes. It trades as ASX:ASX:CSL. Market capitalisation is in the ~A$53B range, recorded as a dated snapshot rather than a live quote.
- Where is CSL based?
- Melbourne
- Is CSL still trading?
- CSL is recorded as actively trading.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
No source is on file for this company yet. Treat everything above as unverified until one is.
Every entity profile on variis is sourced. Not investment advice.